Versor Investments LP Sells 2,680 Shares of Avanos Medical, Inc. (NYSE:AVNS)

Versor Investments LP reduced its stake in shares of Avanos Medical, Inc. (NYSE:AVNS) by 17.5% during the fourth quarter, Holdings Channel reports. The institutional investor owned 12,620 shares of the company’s stock after selling 2,680 shares during the quarter. Versor Investments LP’s holdings in Avanos Medical were worth $201,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of the stock. FMR LLC boosted its position in Avanos Medical by 34.6% during the 3rd quarter. FMR LLC now owns 133,844 shares of the company’s stock valued at $3,216,000 after buying an additional 34,421 shares during the period. Barclays PLC raised its stake in shares of Avanos Medical by 446.2% during the third quarter. Barclays PLC now owns 96,194 shares of the company’s stock valued at $2,311,000 after acquiring an additional 78,583 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Avanos Medical by 12.0% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 108,470 shares of the company’s stock worth $2,607,000 after purchasing an additional 11,613 shares during the period. JPMorgan Chase & Co. grew its stake in shares of Avanos Medical by 6.9% in the third quarter. JPMorgan Chase & Co. now owns 69,571 shares of the company’s stock worth $1,672,000 after purchasing an additional 4,472 shares during the last quarter. Finally, Jane Street Group LLC increased its holdings in Avanos Medical by 35.8% during the 3rd quarter. Jane Street Group LLC now owns 65,650 shares of the company’s stock valued at $1,578,000 after purchasing an additional 17,306 shares during the period. Hedge funds and other institutional investors own 95.17% of the company’s stock.

Avanos Medical Trading Down 0.5 %

AVNS opened at $15.05 on Wednesday. The firm has a market capitalization of $692.35 million, a price-to-earnings ratio of 44.26 and a beta of 1.17. Avanos Medical, Inc. has a one year low of $14.40 and a one year high of $25.36. The business has a 50 day simple moving average of $16.08 and a two-hundred day simple moving average of $19.53. The company has a debt-to-equity ratio of 0.12, a current ratio of 2.22 and a quick ratio of 1.46.

Avanos Medical (NYSE:AVNS) last announced its earnings results on Wednesday, February 26th. The company reported $0.43 EPS for the quarter, beating analysts’ consensus estimates of $0.40 by $0.03. The company had revenue of $179.60 million during the quarter, compared to the consensus estimate of $177.23 million. Avanos Medical had a return on equity of 4.70% and a net margin of 2.30%. Analysts predict that Avanos Medical, Inc. will post 1.32 EPS for the current year.

Avanos Medical Profile

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.